These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30936797)

  • 1. Rare Diseases and Orphan Drugs Accessibility in Bosnia and Herzegovina.
    Guzvic V; Stojakovic N; Jusufovic R; Catic T
    Mater Sociomed; 2018 Dec; 30(4):297-303. PubMed ID: 30936797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HEALTH TECHNOLOGY ASSESSMENT IN CENTRAL-EASTERN AND SOUTH EUROPE COUNTRIES: BOSNIA AND HERZEGOVINA.
    Guzvic V; Catic T; Kostic M
    Int J Technol Assess Health Care; 2017 Jan; 33(3):390-395. PubMed ID: 28434417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient organization involvement and the challenge of securing access to treatments for rare diseases: report of a policy engagement workshop.
    Mikami K; Sturdy S
    Res Involv Engagem; 2017; 3():14. PubMed ID: 29062539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient Access to Medicines for Rare Diseases in European Countries.
    Detiček A; Locatelli I; Kos M
    Value Health; 2018 May; 21(5):553-560. PubMed ID: 29753352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rare diseases and orphan drugs: Latvian story.
    Logviss K; Krievins D; Purvina S
    Orphanet J Rare Dis; 2014 Sep; 9():147. PubMed ID: 25231378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Policies and availability of orphan medicines in outpatient care in 24 European countries.
    Sarnola K; Ahonen R; Martikainen JE; Timonen J
    Eur J Clin Pharmacol; 2018 Jul; 74(7):895-902. PubMed ID: 29632962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries.
    Stawowczyk E; Malinowski KP; Kawalec P; Bobiński R; Siwiec J; Panteli D; Eckhardt H; Simoens S; Agusti A; Dooms M; Pilc A
    Front Pharmacol; 2019; 10():1279. PubMed ID: 31827433
    [No Abstract]   [Full Text] [Related]  

  • 8. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
    Zelei T; Molnár MJ; Szegedi M; Kaló Z
    Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Overview of the Orphan Medicines Market in Turkey.
    Koçkaya G; Wertheimer AI; Kilic P; Tanyeri P; Mert Vural I; Akbulat A; Artiran G; Kerman S
    Value Health Reg Issues; 2014 Sep; 4():47-52. PubMed ID: 29702806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
    Schey C; Milanova T; Hutchings A
    Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient Access to Orphan Drugs Covered by Medical Insurance in China: Real-World Evidence From Patient Survey.
    Wang X; Li SC; Yue X; Li Y; Shi N; Zhao FL; Wu J
    Value Health Reg Issues; 2023 Mar; 34():71-77. PubMed ID: 36587572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.
    Blankart CR; Stargardt T; Schreyögg J
    Pharmacoeconomics; 2011 Jan; 29(1):63-82. PubMed ID: 21073206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rare essentials: drugs for rare diseases as essential medicines.
    Stolk P; Willemen MJ; Leufkens HG
    Bull World Health Organ; 2006 Sep; 84(9):745-51. PubMed ID: 17128345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomic Analysis of Antiepileptic Reimbursement for Neuropathic Pain in Bosnia and Herzegovina - Budget Impact Analysis of Pregabalin.
    Catic T; Jusufovic R; Tabakovic V
    Mater Sociomed; 2018 Jun; 30(2):89-94. PubMed ID: 30061795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilisation of cardiovascular medicines in Republic of Srpska, Bosnia and Herzegovina, 5 years study.
    Markovic-Pekovic V; Stoisavljevic-Satara S; Skrbic R
    Pharmacoepidemiol Drug Saf; 2009 Apr; 18(4):320-6. PubMed ID: 19156752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of patient access to orphan drugs in Turkey.
    Koçkaya G; Atalay S; Oğuzhan G; Kurnaz M; Ökçün S; Sar Gedik Ç; Şaylan M; Şencan N
    Orphanet J Rare Dis; 2021 Feb; 16(1):68. PubMed ID: 33549137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical assessment of belgian reimbursement dossiers of orphan drugs.
    Denis A; Mergaert L; Fostier C; Cleemput I; Hulstaert F; Simoens S
    Pharmacoeconomics; 2011 Oct; 29(10):883-93. PubMed ID: 21905759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Orphan diseases and orphan medicines: a Belgian and European study].
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    J Pharm Belg; 2009 Dec; (4):131-7. PubMed ID: 20183989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [FINANCING OF MEDICINES FOR TREATMENT OF RARE DISEASES OF THE NERVOUS SYSTEM. ORPHAN DRUGS IN RARE NEUROLOGICAL DISEASES].
    Szegedi Márta ; Kosztolányi G; Boncz I; Molnár MJ
    Ideggyogy Sz; 2016 Jan; 69(1-2):37-45. PubMed ID: 26987239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.